Lucid Genomics

Berlin, Germany Founded: 2024 • Age: 2 yrs
Genomic mutations are detected and prioritized via AI platform.

About Lucid Genomics

Lucid Genomics is a company based in Berlin (Germany) founded in 2024 by Uira Souto Melo and M-Hossein Moeinzadeh.. Lucid Genomics has raised $1.44 million across 1 funding round from investors including Caesar, BIF Partners and another.vc. Lucid Genomics offers products and services including Lucid Genome Suite and Variant Detection Tool. Lucid Genomics operates in a competitive market with competitors including Natera, Variantyx, Lantern Pharma, LifeCell and Guangzhou Kang Liming Biotechnology, among others.

  • Headquarter Berlin, Germany
  • Founders Uira Souto Melo, M-Hossein Moeinzadeh
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Lucid Genomics Gmbh
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $1.44 M (USD)

    in 1 rounds

  • Latest Funding Round
    $1.44 M (USD), Seed

    Sep 04, 2024

  • Investors
    Caesar

    & 3 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Lucid Genomics

Lucid Genomics offers a comprehensive portfolio of products and services, including Lucid Genome Suite and Variant Detection Tool. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

AI platform for detecting and prioritizing genome variants in research.

Software for ranking mutations and reducing false positives in diagnostics.

Funding Insights of Lucid Genomics

Lucid Genomics has successfully raised a total of $1.44M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.44 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Seed — $1.4M
  • First Round

    (04 Sep 2024)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2024 Amount Seed - Lucid Genomics Valuation Caesar
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Lucid Genomics

Lucid Genomics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Caesar, BIF Partners and another.vc. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
A Hamburg-based private investment company focused on VC deals.
Founded Year Domain Location
Early-stage venture capital funding is provided to B2B startups.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Lucid Genomics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Lucid Genomics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Lucid Genomics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Lucid Genomics

Lucid Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Natera, Variantyx, Lantern Pharma, LifeCell and Guangzhou Kang Liming Biotechnology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of cell-free DNA testing for oncology, women’s health, and organ health
domain founded_year HQ Location
Genomics data analysis platform for healthcare diagnostics is offered.
domain founded_year HQ Location
Drug and companion diagnostics for multi-drug resistant cancers are developed.
domain founded_year HQ Location
LifeCell is engaged in cord blood banking services.
domain founded_year HQ Location
Cancer detection kits and screening services are provided.
domain founded_year HQ Location
Genetic testing for inherited disorders is provided by the company.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Lucid Genomics

Frequently Asked Questions about Lucid Genomics

When was Lucid Genomics founded?

Lucid Genomics was founded in 2024.

Where is Lucid Genomics located?

Lucid Genomics is headquartered in Berlin, Germany. It is registered at Berlin, Berlin, Germany.

Who is the current CEO of Lucid Genomics?

Uira Souto Melo is the current CEO of Lucid Genomics. They have also founded this company.

Is Lucid Genomics a funded company?

Lucid Genomics is a funded company, having raised a total of $1.44M across 1 funding round to date. The company's 1st funding round was a Seed of $1.44M, raised on Sep 04, 2024.

What does Lucid Genomics do?

Lucid Genomics was founded in 2024 in Berlin, Germany, within the biotechnology and AI sector. An AI-based platform is provided by the company to support analysis of genomic mutations. Detection, interpretation, and prioritization of structural variations across the genome are enabled for healthcare professionals, focusing on those linked to specific genetic diseases. Operations center on tool development for precision medicine applications.

Who are the top competitors of Lucid Genomics?

Lucid Genomics's top competitors include Natera, Lantern Pharma and Nucleus Genomics.

What products or services does Lucid Genomics offer?

Lucid Genomics offers Lucid Genome Suite and Variant Detection Tool.

Who are Lucid Genomics's investors?

Lucid Genomics has 4 investors. Key investors include Caesar, BIF Partners, another.vc, and Max-Planck-Förderstiftung.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available